Clinical trialObsActive not recruiting
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 22 February 2023
- Expected end
- August 2028
- Enrollment
- 185 participants
- Sites
- 2
- Primary outcomes
- Assess molecular and radiological landscape of traditional PDAC tumors in the context of Race/Ethnicity; Compare biological properties of Adipose Tissue dysfunction; Examine the role of Adipose Tissue and PDAC tumor interactions in influencing tumor growth, metastasis, and therapeutic response
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.
Detailed description public domain (ClinicalTrials.gov)
This observational study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations consisting of adult males or females, 18 years of age or older, who self-report as African American (AA) or Non-Hispanic White (NHW), and present to the gastrointestinal (GI) clinic, surgery, or endoscopy at a participating Florida Pancreas Collaborative (FPC) site or University of Mississippi Medical Center (UMMC) with a clinical suspicion or diagnosis of a pancreatic tumor. This study will also include patients who have been previously recruited as part of the FPC study. Our central hypothesis is that adipose tissue (AT) dysfunction contributes to malignant transformation, therapeutic resistance, and poor survival among obese AA pancreatic ductal adenocarcinoma (PDAC) cases and such dysfunction will be characterized by unique biology. The primary objective of this multi-institutional and multidisciplinary translational study is to identify a molecular and imaging profile unique to paired PDAC tumors and AT from AA and harness biological observations to predict therapeutic response and target novel obesity-mediated mechanisms of PDAC development and progression using in vitro, ex vivo, and in vivo techniques and new combinations of drug agents.